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The anaphase promoting complex/cyclosome (APC/
C) is an ubiquitin ligase and core component of the
cell-cycle oscillator. During G1 phase, APC/C binds
to its substrate receptor Cdh1 and APC/CCdh1 plays
an important role in restricting S-phase entry and
maintaining genome integrity. We describe a recip-
rocal feedback circuit between APC/C and a second
ubiquitin ligase, the SCF (Skp1-Cul1-F box). We
show that cyclin F, a cell-cycle-regulated substrate
receptor (F-box protein) for the SCF, is targeted for
degradation by APC/C. Furthermore, we establish
that Cdh1 is itself a substrate of SCFcyclin F. Cyclin F
loss impairs Cdh1 degradation and delays S-phase
entry, and this delay is reversed by simultaneous
removal of Cdh1. These data indicate that the coordi-
nated, temporal ordering of cyclin F and Cdh1 degra-
dation, organized in a double-negative feedback
loop, represents a fundamental aspect of cell-cycle
control. This mutual antagonism could be a feature
of other oscillating systems.
INTRODUCTION
During cell-cycle progression, the ubiquitin proteasome system
controls the destruction of numerous proteins. The best studied
of these are cyclins, the activating subunits of cyclin dependent
kinases (CDKs). Degradation of the mitotic cyclins is catalyzed
by the anaphase promoting complex/cyclosome (APC/C),
a multi-subunit E3 ubiquitin ligase and core component of
the cell-cycle oscillator (reviewed in Sivakumar and Gorbsky,
2015). APC/C was discovered for its role in promoting cyclin B
destruction (King et al., 1995) and is now known to regulate
dozens of proteins involved in cell-cycle progression (Zhang
et al., 2014). The APC/C is required for orderly and unidirectional
progress through the cell-cycle and genome maintenance (Siva-
kumar and Gorbsky, 2015). APC/C utilizes two related substrate
receptor proteins. In mid-mitosis, APC/C binds Cdc20, leadingCell Report
This is an open access article under the CC BY-Nto the degradation of cyclin B and securin, and promoting
anaphase onset. In late mitosis and throughout G1, APC/C binds
to the Cdc20 related protein Cdh1/FZR1 (hereafter referred to as
Cdh1), targeting a myriad of proteins, including the Aurora A ki-
nase and FoxM1 transcription factor (Zhang et al., 2014). Cdc20
and Cdh1 both bind substrates through canonical degron motifs
termed D and KEN boxes, although others have been described
more recently (Barford, 2011). While many APC/C substrates
have been identified, estimates suggest there are more still to
be discovered.
APC/CCdh1 must be turned off at the end of G1 to allow
for S-phase entry. Cdh1 overexpression in G1 cells prevents
S-phase entry, whereas Cdh1 depletion or genetic inactivation
accelerates G1 progression (Sigl et al., 2009; Sørensen et al.,
2001; Yuan et al., 2014). The role of APC/C in restricting S-phase
entry is conserved in budding and fission yeast, flies, worms,
chickens, mice, and humans (Fay et al., 2002; Garcı´a-Higuera
et al., 2008; Kitamura et al., 1998; Sigrist and Lehner, 1997;
Sudo et al., 2001; Wirth et al., 2004). Consistently, Cdh1 is a hap-
loinsufficient tumor suppressor in mice (Garcı´a-Higuera et al.,
2008).
Several reported mechanisms account for APC/C inactivation
during cell-cycle progression. APC/C activity is held in check by
the spindle assembly checkpoint during mitosis (Musacchio,
2015). APC/C is also kept inactive during S and G2 phases, prior
to spindle checkpoint activation. Emi1 (early mitotic inhibitor 1,
FBXO5, Rca1 in flies) was discovered as a key inhibitor of
APC/C (Reimann et al., 2001). When Emi1 is inactivated in flies
and mammals, it results in DNA re-replication during late S and
G2 phases due to unscheduled APC/C activation (Di Fiore and
Pines, 2007; Grosskortenhaus and Sprenger, 2002; Machida
and Dutta, 2007). Cdh1 itself is controlled by both phosphoryla-
tion and ubiquitylation. Cdh1 phosphorylation by cyclin A/CDK2
occludes binding to the APC/C core complex, preventing ligase
activation (Kramer et al., 2000; Lukas et al., 1999). In addition,
Cdh1 degradation can occur through the SCFbTRCP E3 ubiquitin
ligase, and this degradation is also dependent on cyclin A/Cdk2
(Fukushima et al., 2013). Furthermore, it has been reported that
APC/C can auto-ubiquitylate Cdh1, as well as its own E2 en-
zymes, Ubch10 and Ube2S (Listovsky et al., 2004; Rape and
Kirschner, 2004; Williamson et al., 2009a). However, despites 16, 3359–3372, September 20, 2016 ª 2016 The Author(s). 3359
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
these myriad mechanisms implicated in APC/C inactivation, it
remains controversial how APC/CCdh1 is turned off prior to
S-phase entry (Pines, 2011).
The Cullin RING Ligases (CRL) represent the largest E3 ligase
family in humans and together control the destruction of hun-
dreds of proteins involved in virtually all aspects of cellular phys-
iology (Emanuele et al., 2011; Petroski and Deshaies, 2005).
SCF/CRL1 was the first described Cullin ligase and remains
the best understood. SCF ligases recognize their targets through
a family of 69 interchangeable substrate receptors termed F-box
proteins. Cyclin F (CCNF, FBXO1) is the founding member of the
F-box family and was identified in a yeast gain-of-function
screen searching for suppressors of temperature sensitivity in
cdc4-1 cells (Bai et al., 1994). Cyclin F expression oscillates dur-
ing the cell cycle, and the cyclin F amino acid sequence is most
similar to cyclin A. However, cyclin F is an atypical cyclin in that it
does not bind to CDKs (D’Angiolella et al., 2013). Cyclin F hetero-
zygous mice (cyclin F+/) develop normally and homozygous
loss of cyclin F (cyclin F/) is lethal, with null embryos dying
around day E10.5 (Tetzlaff et al., 2004).
Cyclin F has few known substrates, and all that have been
described thus far are linked to either microtubule organization
or DNA metabolism and repair. Among the described cyclin F
substrates are the centrosome protein CP110, and the nucleolar
and spindle associated protein Nusap1 (D’Angiolella et al., 2010;
Emanuele et al., 2011). The RRM2 subunit of ribonucleotide
reductase is an important cyclin F substrate that regulates
genome stability (D’Angiolella et al., 2012). The exonuclease
and DNA repair factor Exo1 was reported to be a cyclin F sub-
strate, as was the replication licensing factor Cdc6 (Elia et al.,
2015; Walter et al., 2016). Cyclin F is unique among F-box pro-
teins in that its transcript levels oscillate throughout the cell cy-
cle. The cyclin F mRNA was identified as cell-cycle regulated
in five independent mRNA profiling studies that examined cell-
cycle transcriptional dynamics, making it the only F-box protein
common among all studies (Bar-Joseph et al., 2008; Grant et al.,
2013; Pen˜a-Diaz et al., 2013; Sadasivam et al., 2012; Whitfield
et al., 2002). The importance of cyclin F in cell-cycle progression
and animal development, combined with its dynamic expression
pattern throughout the cell cycle, prompted us to examine the
mechanisms regulating cyclin F degradation and to identify addi-
tional substrates that it controls.
RESULTS
Cyclin F Is an APC/C Substrate
Several lines of evidence suggested that cyclin F might be an
APC/C substrate. The cyclin F amino acid sequence is most
similar to cyclin A, a bona fide APC/C substrate (den Elzen and
Pines, 2001). Cyclin F protein levels peak in G2/M-phase and
are subsequently diminished in G1, consistent with APC/C-
mediated degradation (Bai et al., 1994; D’Angiolella et al.,
2012). This can be observed in U2OS and HeLa cells synchro-
nized in mitotic prometaphase with nocodazole, isolated by
‘‘shake-off,’’ and followed by immunoblot after release into the
cell cycle (Figures 1A and S1A). Cyclin F levels are lowest in early
G1 phase and then accumulate in lateG1 and throughout the rest
of cell cycle. Cyclin A accumulation begins after cyclin F, consis-3360 Cell Reports 16, 3359–3372, September 20, 2016tent with a previous result (Bai et al., 1994). Finally, Cdh1 levels
decrease as cells enter S-phase and then begin to accumulate
later in the cell cycle, also consistent with prior reports (Benmaa-
mar and Pagano, 2005; Fukushima et al., 2013; Kramer et al.,
2000). We observed similar oscillations in protein abundance in
HeLa cells synchronized at G1/S by a double thymidine block
and release (Figures S2A and S2B).
Prolonged mitotic arrest in nocodazole led to cyclin F and cy-
clin A degradation, consistent with prior reports (Figure 1A)
(D’Angiolella et al., 2012; den Elzen and Pines, 2001; Geley
et al., 2001). Consistently, the time at which cyclin F decreases
around mitosis is indistinguishable from that of cyclin A, an early
mitotic APC/C target (Figure S2A). Cyclin F contains five poten-
tial APC/C D-box degron motifs, which are conserved evolution-
arily (Figures 1B and S1B; amino acid sequence RxxL) (Pfleger
and Kirschner, 2000). Preferred residues surrounding the core
D-box consensus were identified by the Barford lab (He et al.,
2013), and all five potential D-boxes in cyclin F are surrounded
by preferred residues (Figure 1B).
To determine whether cyclin F is an APC/C substrate, we
first applied a simple, in vivo assay, taking advantage of
the ability to activate APC/C in mitotic cells by pharmacolog-
ically inhibiting CDK1. Cyclin F levels decreased significantly
following CDK inactivation with roscovitine in nocodazole-ar-
rested HeLa cells (Figure S1C). Next, we examined cyclin F
abundance following overexpression of the APC/C substrate
receptors Cdc20 and Cdh1. The expression of Cdc20 and
Cdh1 significantly reduced exogenous Myc-cyclin F protein
levels in 293T cells analyzed 24 hr after transfection (Fig-
ure 1C). Importantly, the Cdc20 and Cdh1 overexpression
conditions did not alter the cell cycle, as assayed by flow cy-
tometric analysis of DNA content (Figure S2C). The mRNA
levels of cyclin F, and the well-characterized cell-cycle genes
Cdc20, Plk1, and FoxM1 were also unchanged (Figure S2D).
Transfection of FLAG-Cdh1 also reduced endogenous cyclin
F protein levels (Figure 1D). Moreover, the decline in cyclin F
caused by Cdh1 overexpression was fully reversed by protea-
some inhibition using either MG-132 or bortezomib (Figure 1E),
demonstrating that Cdh1 causes the proteasome-mediated
degradation of cyclin F. These data suggest that APC/CCdh1
regulates cyclin F degradation.
We next examined the impact of pharmacological APC/C
inactivation on cyclin F. We treated cells with the small molecule
inhibitor proTAME after synchronization in G1, the primary time
during the cell cycle when APC/CCdh1 is active (Cappell et al.,
2016; Zeng et al., 2010). U2OS cells were synchronized using
a nocodazole block-and-release and then acutely treated with
proTAME. APC/C inhibition leads to an increase in the abun-
dance of cyclin F, and the APC/C substrate cyclin B (Figure 2A).
Cyclin F levels were also increased in asynchronously dividing
293T, HeLa, and U2OS cells treated with proTAME for just
2.5 hr (Figure S1D).
Cdh1 depletion by small interfering RNA (siRNA) resulted in an
increase in cyclin F abundance compared to cells treated with
control siRNAs targeting firefly luciferase (FF; Figure 2B). The
APC/CCdh1 substrate FoxM1 is also increased by Cdh1 deple-
tion. Likewise, Cdc20 depletion augments cyclin F levels to a
similar degree as cyclin A, a known target of APC/CCdc20 (den
Figure 1. Cdh1 Regulates the Abundance and Stability of Cyclin F
(A) U2OS cells were synchronized in mitosis with nocodazole, isolated by ‘‘shake-off,’’ and analyzed by immunoblot after release into the cell cycle.
(B) Domain structure of human cyclin F showing the position of its cyclin homology domain, F-box domain, and five putative APC/C degron motifs. Preferred
residues around the putative D-box motifs are shown in red.
(C) FLAG-Cdc20 or FLAG-Cdh1 was ectopically expressed in 293T cells in combination with Myc-cyclin F. Cells were harvested after 24 hr and analyzed by
immunoblot.
(D) FLAG-Cdh1 was ectopically expressed in 293T cells and reduced the level of endogenous cyclin F at 24 and 48 hr after transfection.
(E) Myc-cyclin F and FLAG-Cdh1 were ectopically expressed in 293T cells for 24 hr. Cells were treated with the proteasome inhibitors MG-132 (10 mM) or
bortezomib (100 nM) 4 hr prior to harvesting.Elzen and Pines, 2001; Geley et al., 2001). Treatment with pro-
teasome inhibitors blunted the effect of Cdc20 depletion on
both proteins, indicating that cyclin F, like cyclin A, is targeted
to the proteasome by APC/C in mitosis (Figure S3A). We next
examined changes in cyclin F stability because pharmacological
APC/C inactivation, and gain- and loss-of-function genetic ap-
proaches suggested that APC/C regulates cyclin F post-tran-
scriptionally. We monitored cyclin F half-life after inhibiting pro-
tein synthesis with cycloheximide (CHX). Cells were depleted
for 48 hr with siRNA targeting Cdh1 or FF, synchronized into
G1 using nocodazole block and release, and then treated with
CHX. Cdh1 depletion significantly elevated cyclin F levels in G1
cells and extended its half-life to 173.2 min from 31.5 min (Fig-
ure 2C). We conclude that the abundance and stability of cyclin
F are governed by APC/CCdh1 during G1 phase.
The above data strongly suggest that cyclin F is an APC/C
substrate. Consistently, endogenous cyclin F co-precipitated
endogenous Cdh1 from 293T cell extracts (Figure 2D). In addi-tion, exogenously expressed cyclin F co-precipitated endoge-
nous Cdh1 and Cdc20 (Figure S3B). We ectopically expressed
Myc-cyclin F and FLAG-Cdh1 in 293T cells to establish a system
to test the interaction between cyclin F and Cdh1. Cells were
treated with the proteasome inhibitor MG-132 prior to lysis to
normalize protein levels across conditions and increase the
abundance of low abundance proteins, improving the ability to
detect E3-substrate interactions by co-immunoprecipitation
(coIP). Under these conditions, we could readily coIP Myc-cyclin
F and FLAG-Cdh1, regardless of which protein was immunopuri-
fied (Figure 2E).
To determine whether Cdh1 could enhance the ubiquitylation
of cyclin F in cells, cyclin F and Cdh1 were co-expressed in the
presence of a hexa-histidine tagged (6HIS) ubiquitin. Since ubiq-
uitin causes the degradation of substrates, cells were treated
with MG-132 prior to lysis and ubiquitin pull-down. Lysis was
performed under strong denaturing conditions and ubiquitin
was recovered on nickel agarose. We immunoblotted for cyclinCell Reports 16, 3359–3372, September 20, 2016 3361
Figure 2. Cyclin F Degradation Is Regulated by the APC/C
(A) U2OS cells synchronized in G1 phase by mitotic block and release and treated with the APC/C inhibitor proTAME for 90 min.
(B) Cyclin F or Cdh1 were depleted from T47D cells using siRNA for 48 hr. Negative control siRNA (siFF) targets firefly luciferase.
(C) Depletion of Cdh1 using siRNA extended the half-life of cyclin F. Cells were depleted of Cdh1 by siRNA (same as B), synchronized in G1 by nocodazole
block and release, and then treated with cycloheximide (CHX) to analyze cyclin F stability. On the right is a semiquantitative analysis of the cyclin F signal. Blue
diamonds, negative control; maroon squares, Cdh1 depletion. Cyclin F signal relative to the Ran loading control is shown on the y axis (error bars indicate SD).
(D) Endogenous Cyclin F was precipitated from 293T whole-cell extracts. Cells were treated with MG-132 prior to lysis.
(E) Myc-cyclin F and FLAG-Cdh1 were transfected into 293T cells, and each was separately recovered and analyzed by immunoblot. Cells were treated with
MG-132 for 4 hr prior to lysis.F to evaluate its relative level of ubiquitylation. Cyclin F ubiquity-
lation was significantly enhanced by the ectopic expression of
Cdh1, suggesting that APC/CCdh1 enhances cyclin F ubiquityla-
tion in vivo (Figure 3A). Next, we analyzed cyclin F ubiquitylation
by APC/CCdh1 in vitro. APC/C was isolated from G1-synchro-
nized HeLa cell extracts using an anti-Cdc27 antibody. Isolated
APC/C was used in an ubiquitylation reaction with added ubiqui-
tin, E1, E2, Cdh1, and ATP. APC/C efficiently ubiquitylated wild-
type cyclin F in vitro, providing strong evidence that cyclin F is a
direct APC/C substrate (Figure 3B).
Cyclin F contains five potential D-box motifs (Figure 1B). We
predicted that altering the sequence of one or more of the puta-
tive D-boxes in cyclin F would interfere with Cdh1 binding. We
disrupted the D-boxes in cyclin F by changing the essential argi-3362 Cell Reports 16, 3359–3372, September 20, 2016nine and leucine residues to alanine in each motif individually
(RxxL to AxxA). We measured binding between Myc-cyclin F
and FLAG-Cdh1 by coIP in 293T cells (treated with MG-132 prior
to lysis). Several of the D-boxes appeared to contribute to Cdh1-
cyclin F binding (Figure S4A). Further analysis revealed that
mutating D-boxes one and four together (cyclin FDBM1/4) abro-
gated the ability of cyclin F to interact with Cdh1 by coIP (Fig-
ure 3C). We therefore tested the ability of this non-interacting cy-
clin F mutant to be ubiquitylated in vitro. We did not detect any
appreciable ubiquitylation when using cyclin FDBM1/4 as a sub-
strate in vitro (Figure 3B). The conserved arginine and leucine
residues in D-boxes 1 and 4 are predicted to be on the surface
of cyclin F based on homology modeling (Figures S3C–S3E). In
addition, mutation of only the first D-box in cyclin F (cyclin
Figure 3. Cdh1 Regulates Cyclin F Ubiquitylation through Canonical D-box Degron Motifs
(A) Myc-cyclin F, FLAG-Cdh1 and 6HIS-ubiquitin were expressed in 293T cells, and ubiquitin conjugates were recovered on nickel agarose under denaturing
conditions (6M Guanidine). Ubiquitylation of cyclin F was analyzed by immunoblot. Cells were treated with MG-132 prior to harvesting and lysis.
(B) APC/C ubiquitylates cyclin F in vitro. APC/Cwas immunopurified fromG1HeLa cell extracts andmixedwith in vitro translated cyclin F (WT ormutants), E1, E2,
ATP, ubiquitin, and Cdh1.
(C) Myc-cyclin FWT or Myc-cyclin F harboring mutations in D-boxes 1 and 4 (DBM1/4) were co-transfected with FLAG-Cdh1 and analyzed using Myc IP after
treatment with MG132 for 4 hr.
(D) FLAG-Cdh1was ectopically expressed in 293T cells in combination withMyc-cyclin FWT orMyc-cyclin FDBM1/4. Cdh1 catalyzed the degradation of Myc-cyclin
FWT but not Myc-cyclin FDBM1/4.FDBM1), which partially impaired binding, gave an intermediate
defect on ubiquitylation in vitro. These data strongly argue that
cyclin F is targeted for ubiquitylation and degradation by APC/
CCdh1. Accordingly, whereas Cdh1 catalyzes the degradation
of cyclin FWT when the two proteins are ectopically expressed
together in cells, cyclin FDBM1/4 is resistant to Cdh1-mediated
degradation in this assay (Figure 3D). We conclude that cyclin
F is an APC/C substrate.
Cdh1 Is a Cyclin F Substrate
Cdh1 levels are decreased in S-phase cells (Figures 1A and S2A)
(Benmaamar and Pagano, 2005; Kramer et al., 2000). Pagano
and colleagues first noted the dependence of this S-phase
degradation on Cul1, although they did not establish the relevant
substrate receptor (Benmaamar and Pagano, 2005). Wei and
colleagues reported that Cdh1 could be targeted by SCFbTRCP,
in a cyclin A/CDK2- and Plk1-dependent mechanism (Fukush-
ima et al., 2013). However, since both kinases are activated laterin the cell cycle it is unclear whether they account for Cdh1
destruction in late G1 and early S-phase.
We noted that the reappearance of cyclin F was coincident
with the decrease in Cdh1 (Figure 1A). Additionally, Cdh1 and cy-
clin F levels both decreased when the proteins were expressed
together, compared to expressing either alone (Figure 4A).
Together, these data suggest the possibility that Cdh1 might
be also a substrate of SCFcyclin F. Titrated overexpression of cy-
clin F reduced endogenous Cdh1 levels (Figure 4B). Cyclin F
expression also reduced the abundance of exogenously ex-
pressed Cdh1, suggesting that the reduction in Cdh1 is caused
by post-translational mechanisms (Figures 4A and 4C). Impor-
tantly, the cyclin F overexpression conditions did not alter the
cell cycle or the expression of Cdh1, Cdc20, Plk1, and FoxM1
(Figures S2C and S2D). To confirm that the reduction in Cdh1
following ectopic cyclin F expression is dependent on the activity
of Cullin Ring Ligases, we inhibited their activity using a small-
molecule inhibitor of the neddylation cascade, MLN4924 (SoucyCell Reports 16, 3359–3372, September 20, 2016 3363
Figure 4. Cdh1 Abundance and Stability Are Regulated by Cyclin F
(A) Ectopic expression of Myc-cyclin F and FLAG-Cdh1 in 293T cells reduces the level of both proteins.
(B) Myc-cyclin F reduced the abundance of endogenous Cdh1 in a dose-dependent manner when expressed in 293T cells.
(C) Myc-cyclin F overexpression reduces the abundance of FLAG-Cdh1 when expressed in 293T cells. The degradation of Cdh1 was rescued by the neddylation
inhibitor MLN4924.
(D) Depletion of cyclin F using two independent siRNA reagents increases exogenously expressed FLAG-Cdh1 in 293T cells.
(E) Cdh1 levels were analyzed in cyclin F null (/) MEFs and in a corresponding control cell line (+/).
(F) Control and cyclin F knockout HeLa cells were analyzed either in asynchronous populations (lanes 1 and 2), synchronized in S-phase with aphidicolin (lanes 3
and 4), or 6 hr after aphidicolin release (lanes 5 and 6). During aphidicolin block serum was reduced to mitigate DNA damage.
(G) Control and cyclin F knockout HeLa cells were treated with cycloheximide and Cdh1 half-life was analyzed.et al., 2009). Myc-cyclin F and FLAG-Cdh1were co-expressed in
293T cells for 18 hr and then treated with MLN4924 for 6 hr prior
to harvesting for immunoblot. The degradation of Cdh1 caused
by cyclin F expression could be reversed by MLN4924 (Fig-
ure 4C). Accordingly, depletion of cyclin F using siRNA increased
endogenous Cdh1 abundance (Figure 2B). Furthermore, siRNA
depletion of cyclin F using either of two independent oligonucle-
otides increased the abundance of exogenously expressed
FLAG-Cdh1 (Figure 4D). To confirm the importance of cyclin F
in regulating Cdh1 we examined cyclin F null mouse embryo
fibroblasts (MEFs) (Tetzlaff et al., 2004). Cyclin F wasmore abun-
dant in Cdh1 knockout MEFs relative to WT controls (Figure 4E).3364 Cell Reports 16, 3359–3372, September 20, 2016This was true in both asynchronous MEFs, and in those synchro-
nized in G0/G1 by serum deprivation (Figure S4C). These data
demonstrate that Cdh1 abundance is regulated by cyclin F in
mouse and human cells and suggest that Cdh1 is itself a sub-
strate of SCFcyclin F.
We generated cyclin F knockout cells in a HeLa background
using Crispr/Cas9 technology to further assess the conse-
quence of cyclin F loss in human cells. We generated two inde-
pendent single guide RNAs (sgRNA#1 and sgRNA#2) that target
the 50 end of the cyclin F locus and used them to generate two
independent cyclin F knockout cell lines. Cyclin F knockout
HeLa cells show an increase in steady-state Cdh1 levels (Figures
4F, 4G, S4D, and S4E). Notably, one of the cyclin F knockout cell
lines (generated using guide #2) showed a more significant in-
crease in Cdh1 levels (Figure S4D, explained below). To test
the ability of cyclin F to control Cdh1 in S-phase, when Cdh1 is
targeted for degradation, we examined cells synchronized using
aphidicolin. In this experiment, we temporarily reduced serum in
themedia (for all conditions) to mitigate aphidicolin induced DNA
damage. Cdh1 abundance was significantly higher in cyclin F
knockout cells compared to controls (Figure 4F). This was also
true in S-phase synchronized cells, suggesting that cyclin F reg-
ulates Cdh1 during S-phase (Figure 4F). Finally, after release
from arrest (and following the re-introduction of serum), cyclin
F knockout cells still had significantly increased levels of Cdh1,
suggesting that these results were not related to serum with-
drawal. Similar results were found in an experiment in which
serum was not removed during aphidicolin treatment (data not
shown).
We further utilized these HeLa cyclin F knockout cell lines to
examine Cdh1 stability after CHX treatment. We performed
these assays in both cyclin F knockout cell lines (made using
sgRNA#1 and sgRNA#2). Cdh1 half-life was significantly longer
in cyclin F knockout cells compared to controls (Figures 4G,
S4E, and S4F). Interestingly, longer immunoblot exposures re-
vealed very low but detectable cyclin F expression in the
sgRNA#1 knockout cell line. This fortuitously provided us with,
in essence, an allelic series for cyclin F. Accordingly, Cdh1
showed an intermediate half-life in the sgRNA#1 cell line (t1/2 =
60.0 min), in which the knockout is incomplete (Figure S4E), ex-
hibiting a stability between that of the control (t1/2 = 43.3min) and
the sgRNA#2 line (t1/2 = 90.0 min), in which cyclin F levels are un-
detectable (Figure S4F). A significantly extended Cdh1 stability
was also observed after cyclin F depletion with siRNA (Fig-
ure S4B). We conclude that cyclin F regulates the stability of
Cdh1.
Since cyclin F is not present in early G1, and Cdh1 is degraded
in S-phase, we predicted that SCFcyclin F targets Cdh1 for degra-
dation during S-phase. We synchronized control and cyclin F
knockout cells at various points in the cell cycle after release
from a double thymidine block and examined Cdh1 stability by
CHX chase. Cdh1 half-life was extended in S and G2 phases
by cyclin F knockout, measured 2 and 8 hr after release, res-
pectively (Figure S5). In addition, Cdh1 stability was indistin-
guishable between cyclin F knockout and control cells in G1,
measured 13 hr after release. We therefore conclude that cyclin
F regulates Cdh1 stability during S and G2 phases.
Canonical cyclins that bind CDKs recognize Cy motifs when
engaging substrates for phosphorylation (Schulman et al.,
1998). Cyclin F also binds to Cy motifs in its substrates to con-
trol their ubiquitylation (D’Angiolella et al., 2013). Intriguingly, the
Cdh1 amino acid sequence contains 12 potential Cy motifs (Fig-
ure 5A). We tested the possibility that cyclin F directly catalyzes
Cdh1 ubiquitylation and degradation by searching for Cy motifs
in Cdh1 that regulate binding to and degradation by cyclin F. We
narrowed down the interacting region using truncation muta-
genesis. An amino-terminal truncation deleting the first 100
amino acids in Cdh1 impaired its ability to bind to cyclin F by
coIP (Figure 5B). We therefore examined possible Cy motifs in
this region. Within the first 13 amino acids of Cdh1 there arethree partially overlapping Cy motifs (Figure 5A). One of these
motifs has the sequence RRL, which is identical to the cyclin
F interacting Cy motif in the known substrate CP110 (D’Angio-
lella et al., 2010). We tested whether these three Cy motifs are
important for cyclin F binding by substituting the conserved
residues for alanine (aa 7–14 changed from RRLLRQIV to
AAAAAQAV). This Cdh1 Cy motif 1–3 mutant (Cdh1CM1–3) is
impaired in its ability to bind to cyclin F by coIP (Figures 5C
and S6). Notably, this mutation retains some binding to cyclin
F, as we still observe residual cyclin F co-purifying with both
Cdh1CM1–3 and the truncated version lacking the first 100 aa,
particularly on longer immunoblot exposures (Figures 5B, 5C,
and S6). Cdh1CM1–3 still binds to cyclin A, indicating it is gener-
ally folded properly and functional (Figure S6). Interestingly, Cy
motif 12 (CM12; amino acids 445–447, sequence RVL), which
mediates binding to cyclin A (Sørensen et al., 2001), also con-
tributes to cyclin F binding (Figure 5C). We conclude that the
overlapping Cy motifs in the amino-terminal 13 residues of
Cdh1 specifically control binding to cyclin F.
Identifying Cy motifs in Cdh1 that control binding to cyclin F
suggests that SCFcyclin F directly catalyzes Cdh1 ubiquitylation.
Consistently, cyclin F expression catalyzes the degradation of
Cdh1WT (Figures 4A–4C and 5D), but not Cdh1CM1–3, when co-
expressed in 293T cells (Figure 5D). We next tested the ability
of cyclin F to enhance Cdh1 ubiquitylation in cells using the
6HIS-ubiquitin pull-down assay (treated with MG-132 and pulled
down under denaturing conditions). In this assay, cyclin F
enhanced the ubiquitylation of Cdh1 (Figure 5E). Taken together,
these data show that Cdh1 is targeted for ubiquitylation and
degradation by cyclin F. Thus, SCFcyclin F and APC/CCdh1 bio-
chemically antagonize one another, forming a reciprocal feed-
back circuit.
Cyclin F was identified as a suppressor of temperature sensi-
tive cdc4-1 yeast cells (Bai et al., 1994). Cdc4 is a yeast F-box
protein, responsible for targeting the CDKi Sic1 for degradation.
Consequently, cdc4-1 cells grown at the restrictive temperature
have elevated Sic1 levels and arrest in G1 because they are
unable to activate CDK (Bai et al., 1996; Schwob et al., 1994).
The lethality of cdc4-1 cells (grown at the restrictive temperature)
can be suppressed by expressing Skp1, which activates the
impaired SCFCdc4 ligase. Alternatively, cdc4-1 cells can be
rescued by expression of the yeast B-type cyclin Clb4, which ac-
tivates CDKs despite high Sic1 levels (Bai et al., 1996).
Unlike Skp1, expression of cyclin F does not diminish Sic1
levels, excluding the possibility that cyclin F restores viability
by reactivating SCFCdc4. Moreover, cyclin F cannot bind CDKs,
excluding the possibility that it restores viability in amanner anal-
ogous to Clb4 (Bai et al., 1996). We reasoned that overproduc-
tion of human cyclin F might target yeast Cdh1 for degradation.
Cdh1 destruction might allow for the accumulation of APC/C
substrates like Clb4 and the other B-type cyclins. Therefore,
the original plasmid that identified cyclin F as a suppressor of
cdc4-1 lethality (YEP PGAL-cyclin F) was introduced into
S. cerevisiae that have endogenous Cdh1 tagged with 13xMyc.
Cdh1-Myc levels were virtually undetectable following cyclin F
overexpression in yeast (Figure 5F). We conclude that cyclin F
can regulate the abundance of Cdh1 in yeast, mouse, and
human cells.Cell Reports 16, 3359–3372, September 20, 2016 3365
Figure 5. Cyclin F Regulates Cdh1 Degradation through Binding to Canonical Cy Motif Sequences
(A) Schematic of Cdh1 showing the position of the WD40 repeat domain and 12 putative Cy motifs.
(B) Truncated versions of Cdh1 were tested for binding to cyclin F by coIP in transfected 293T cells treated with MG132 prior to IP.
(C) Myc-cyclin F and FLAG-Cdh1 (WT and mutants) were expressed in 293T cells, and binding was analyzed by IP following treatment with MG-132.
(D) Myc-cyclin F, Flag-Cdh1WT and FLAG-Cdh1CM1–3 were expressed together in 293T cells and Cdh1 degradation was examined. The non-binding Cdh1CM1–3
mutant is resistant to cyclin F-mediated degradation.
(E) FLAG-Cdh1, Myc-cyclin F, and 6HIS-ubiquitin were expressed together in 293T cells. 6HIS-ubiquitin was isolated under denaturing conditions and
endogenous Cdh1 was analyzed by immunoblot. Cells were treated with MG132 prior to harvesting.
(F) Human cyclin F was expressed in a yeast strain where endogenous yeast Cdh1 was tagged with Myc.Cyclin F and Cdh1 Are Antagonistic in Regulating G1
Progression and S-Phase Entry
APC/C is inactivated at the G1-S boundary, and we found that
cyclin F protein begins to accumulate prior to cyclin A in late
G1 (Figure 1A). Since Cdh1 plays an evolutionarily conserved
role in restricting S-phase entry, we reasoned that cyclin F would
be important for the timely initiation of DNA replication. Cyclin F
was depleted using siRNA from non-transformed RPE1 cells.
Serum was then withdrawn to synchronize the population in3366 Cell Reports 16, 3359–3372, September 20, 2016G0/G1. We monitored S-phase entry over time using cell-cycle
flow cytometric analysis of DNA content after re-feeding with
media containing serum. Cyclin F depletion substantially blunted
S-phase entry kinetics in this assay (Figure 6A). While 13.4% of
control-depleted cells had entered S-phase by 28 hr after re-
feeding, the cyclin F-depleted cell population had no increase
in the percentage of S-phase cells by that time (Figure 6A). These
data indicate an important role for cyclin F inmediating cell-cycle
entry in non-transformed cells.
Figure 6. Cyclin F Regulation of G1 Progression Is Dependent on Cdh1
(A) Non-transformed RPE1 cells were treated with siRNA targeting cyclin F or FF. Cells were synchronized in G0/G1 by serumwithdrawal. After refeeding, entry in
S-phase was monitored at the designated time points by flow cytometry.
(B) U2OS cells were synchronized in mitosis with nocodazole following depletion with siRNA targeting FF, Cdh1, cyclin F, or cyclin F and Cdh1 together. After
release from nocodazole, cells were pulsed with EdU for 30 min, fixed, and analyzed for EdU incorporation. The percent of nuclei that are EdU positive is shown
(performed in triplicate, *p% 0.01; **p% 0.004; ***p% 0.0005; p values were calculated using unpaired t test). Error bars indicate SD of mean. Immunoblot on left
shows knockdown at zero time point (in mitosis). Representative images of EdU positive cells (top) and DNA content (bottom) are shown below.The experiment above monitors exit from G0 and transit
through G1. To isolate the role of cyclin F in G1 progression,
wemonitored cells progressing throughG1 after synchronization
in mitosis. U2OS cells were transfected with siRNA for 24 hr, fol-
lowed by the addition of nocodazole. Mitotic cells were isolated
by ‘‘shake-off,’’ washed extensively, and then re-plated in fresh
media. The BrdU (5-bromo-20-deoxyuridine) analog EdU (5-ethy-
nyl-20-deoxyuridine) was added 30 min prior to fixing cells onplates. This allowed us to identify cells that had progressed
into S-phase using cell imaging. In this assay, we compared cells
depleted of cyclin F, Cdh1, or both proteins simultaneously. We
checked cell lysates at the zero time point to ensure that cyclin F
and Cdh1 had been depleted (Figure 6B, left). Depletion of either
protein had no detectable effect on the abundance of the other,
suggesting post-translational regulation of their ability to control
each other during mitosis. Cdh1 depletion accelerated S-phaseCell Reports 16, 3359–3372, September 20, 2016 3367
Figure 7. A Model Depicting the Interplay between APC/CCdh1 and
SCFcyclin F during Cell-Cycle Progression
Cyclin F levels are diminished inmitosis and early G1 and then re-appear late in
G1 coincident with the loss of Cdh1. The location of relative motifs in Cdh1 and
cyclin F that mediate their interaction are shown. The proposed configurations
of the cyclin F-Cdh1 interaction when bound to either APC/C in G1 or the SCF
in S-phase is depicted graphically.entry, in agreement with previous reports (Figure 6B) (Garcı´a-Hi-
guera et al., 2008; Sigl et al., 2009; Yuan et al., 2014). Forty-one
percent of control cells were incorporating EdU at 6 hr after no-
codazole release, whereas 77% of Cdh1-depleted cells had
entered S-phase at the same time point. Cyclin F depletion blunt-
ed the accumulation of EdU positive cells, consistent with a role
for cyclin F in mediating S-phase entry. Only 12% of cyclin
F-depleted cells had incorporated EdU, compared to 41% of
control cells and 71% of Cdh1-depleted cells, 6 hr after release
(Figure 6B). Importantly, the decreased rate of S-phase entry in
cyclin F-depleted cells was completely reversed by co-depletion
of Cdh1 (Figure 6B). Similar results were obtained in a separate
experiment when cells were analyzed for EdU incorporation by
flow cytometry (Figure S7A). In addition, we observed a similar
effect on S-phase entry after cyclin F and Cdh1 depletion using
multiple siRNA oligonucleotides in both HeLa and U2OS cells
(Figures S7B and S7C). Together, these results demonstrate
an important role for cyclin F in the timing of S-phase entry and
that the S-phase entry delay in cyclin F-depleted cells is depen-
dent on Cdh1. This suggests antagonism between Cdh1 and cy-
clin F in regulating the initiation of DNA replication.DISCUSSION
Our data indicate that the coordinated, temporal ordering of
cyclin F and Cdh1 degradation is a key aspect of cell-cycle con-
trol (summarized in Figure 7). We show that cyclin F and Cdh1
antagonize each other biochemically, since cyclin F is a sub-
strate of the APC/C, and Cdh1 is a substrate of SCFcyclin F.
Further, cyclin F depletion slows G1 progression, and this is fully
rescued by co-depletion of Cdh1. We therefore conclude that
Cdh1 and cyclin F exist in a mutually antagonistic feedback cir-
cuit. The regulation of APC/C and SCFcyclin F by one another
represents a unique mechanism for temporally controlling E33368 Cell Reports 16, 3359–3372, September 20, 2016ligases. This direct, ubiquitin dependent, feedback could repre-
sent a common feature among other oscillating systems.
Recently, cyclin F was reported to control the stability of the
replication licensing protein Cdc6. We recovered Cdc6 in a pro-
teomic screen for cyclin F interactors and have confirmed their
binding by coIP (unpublished data) (Walter et al., 2016). The
regulation of Cdc6 by cyclin F prevents DNA re-replication. We
have shown here that depletion of cyclin F increases the abun-
dance of Cdh1, whose overexpression also induces re-replica-
tion (Sørensen et al., 2000). Together, these results suggest
that cyclin F might restrain re-replication by repressing Cdc6
and Cdh1 levels. Moreover, since depletion of the APC/C inhib-
itor Emi1 also causes re-replication (Machida and Dutta, 2007),
we speculate that cyclin F and Emi1 redundantly regulate APC/
C inactivation in S/G2 phase of the cell cycle.
Mechanistic Insights into the APC/C-SCFcyclin F Circuit
The APC/C is activated in mitosis and remains on throughout
G1 phase. During this time, cyclin F stability and abundance
are regulated by APC/C. Our data suggest that cyclin F degra-
dation begins in mitosis and that cyclin F is destroyed in a
manner analogous to its most closely related cyclin, cyclin A.
This suggests that cyclin F turnover likely begins with APC/
CCdc20, and then it is maintained at low levels throughout G1
phase by APC/CCdh1. In support of this notion, cyclin F is
largely degraded in nocodazole-treated cells, and its abun-
dance and stability are maintained at low levels in G1 phase
by APC/CCdh1 (D’Angiolella et al., 2012). Cyclin F then accumu-
lates in late G1 and into S-phase, and during this time cyclin F
targets Cdh1 for degradation. Accordingly, the levels of Cdh1
and cyclin F are anti-correlated at the G1/S boundary following
mitotic synchronization, and there is antagonism between cy-
clin F and Cdh1 in regulating S-phase entry. Moreover, cyclin
F regulates Cdh1 in S and G2 phases, but not in G1 cells
(when cyclin F levels are lowest).
Based on these observations, we predict that the cell exists in
at least two different biochemical states with respect to the
Cdh1-cyclin F circuit. The first state is one that is permissive
for APC/C targeting of cyclin F and occurs in mitosis and early
G1 phase. Alternatively, the cellular milieu can be permissive
for SCFcyclin F targeting of Cdh1 in S and G2 phases, contributing
to APC/C inactivation. Cdh1 and cyclin F eventually co-accumu-
late, both reaching their highest levels around G2/M. Thus, there
is likely a third state that permits the increasing levels of both pro-
teins and which suppresses their antagonism. The identification
of upstream elements and themechanisms bywhich they dictate
these different states is an important area of future study.
An interesting feature of the cyclin F-Cdh1 interaction pertains
to the sites that mediate binding. A compound Cy motif in amino
terminus of Cdh1 is important for its regulation by cyclin F. The
site presumably contacts the hydrophobic patch in the cyclin ho-
mology domain of cyclin F that serves as a Cymotif receptor. We
predict that, when this amino-terminal Cy motif in Cdh1 binds to
the cyclin homology domain in cyclin F, their interaction is
permissive for Cdh1 ubiquitylation (Figure 7). Notably, the hydro-
phobic patch on cyclin F is also the region of the protein that con-
tains the D-boxes responsible for APC/C targeting. In fact, the
two critical D-boxes that we mapped form part of the core of
the hydrophobic patch. One of these D-boxes is the well-estab-
lished MRYIL motif, analogous to the MRAIL motif in cyclins A
and B (D’Angiolella et al., 2010; Schulman et al., 1998). As de-
picted in Figure 7, we predict that these D-box motifs tether cy-
clin F to the APC/C, enabling cyclin F ubiquitylation in mitosis
and early G1. A version of cyclin F harboring mutations in these
D-box consensus motifs is resistant to Cdh1 degradation in vivo
and cannot be ubiquitylated by APC/C in vitro.
Thus, we hypothesize that cyclin F and Cdh1 engage each
other in at least two possible conformational states, depending
on which protein is being targeted for degradation. One occurs
in early G1, in which the D-box receptor on Cdh1 is bound to
the hydrophobic patch/D-box in cyclin F. The second exists in
S-phase when the Cy motif in Cdh1 is bound to the hydrophobic
patch/D-box in cyclin F. Consistently, changing amino acids in
the D-box/Cy receptor on cyclin F completely blocked binding
to Cdh1 by coIP, since these changes abolish the formation of
both binding states. Furthermore, we observed some residual
binding when the Cy motif in Cdh1 was altered, since the pro-
teins could still bind in the alterative conformation. We speculate
that post-translational modifications surrounding these sites
may mediate the ability of cyclin F to target Cdh1 for ubiquityla-
tion and vice versa.
APC/C Regulation throughout the Cell Cycle
The APC/C is the most complex E3 ligase that has been
described with a mass of >1.2 mDa and 14 individual protein
components, some present in duplicate copies (Sivakumar and
Gorbsky, 2015). The role of APC/CCdh1 in restraining cell-cycle
entry is conserved from yeast to humans. Its importance in con-
trolling cell-cycle events and genome stability is highlighted by
the multiple mechanisms that have evolved to control its activity
at different points in the cell cycle. APC/C is kept inactive by the
spindle checkpoint in early mitosis (Musacchio, 2015). In addi-
tion, Emi1 potently inhibits APC/C activity during interphase. In
both humans and flies, Emi1 depletion results in DNA re-replica-
tion due to the unscheduled re-activation of APC/C in late S and
G2 phases (Di Fiore and Pines, 2007; Machida and Dutta, 2007).
These data are most consistent with a primary role for Emi1 in
controlling APC/C later in the cell cycle. Consistently, reports
in flies and animal cells have shown that Emi1 is dispensable
for G1-S progression (Di Fiore and Pines, 2007; Grosskorten-
haus and Sprenger, 2002). Recent results have also shown an
alternative role for Emi1 in the irreversibility of APC/C inactivation
in S-phase (Cappell et al., 2016).
APC/CCdh1 is also regulated by phosphorylation and ubiquity-
lation of Cdh1. Cyclin A-Cdk2 sits at the nexus of both of
these pathways. Cyclin A/CDK2 phosphorylation of Cdh1 im-
pairs its binding to the APC/C core complex (Kramer et al.,
2000; Lukas et al., 1999). In addition, sequential phosphorylation
of Cdh1 first by cyclin A/CDK2, and then by Plk1, triggers Cdh1
degradation through the SCFbTRCP ubiquitin ligase, via recogni-
tion of a non-canonical phospho-degron motif (Fukushima
et al., 2013). However, careful kinetic analysis by Zetterberg
and colleagues demonstrated that the accumulation of cyclin A
begins after the start of DNA replication, making it unlikely that
cyclin A/CDK2 inhibits APC/CCdh1 prior to the start of S-phase
(Erlandsson et al., 2000).Other researches have suggested that APC/C-dependent
degradation of its own E2s contributes to its inactivation,
arguing that the APC/C is an autonomous oscillator that self-
inactivates at the end of G1 (Rape and Kirschner, 2004; William-
son et al., 2009a). However, the notion that the APC/C is inacti-
vated through E2 auto-ubiquitylation has not been universally
accepted (Pines, 2011). Others have found that the levels
of the APC/C E2s are insufficiently reduced to impair APC/C
activity, and that UbcH10 accumulates as cells approach
S-phase (Walker et al., 2008).
Finally, APC/CCdh1 was reported to auto-ubiquitylate Cdh1
(Listovsky et al., 2004). This interpretation was based on the
identification of two D-box consensus motifs in Cdh1 itself.
These potential D-boxes were required for Cdh1 degradation
in S-phase (Listovsky et al., 2004). Interestingly, both of these
potential D-boxes are also Cy motifs (amino acids 7–10:RRLL
and amino acids 28–31:RRTL). Notably, the first of these
D-box/Cy motif hybrids (RRLL at amino acids 7–10) is part of
the compound N-terminal Cy motif that mediates cyclin F bind-
ing and that is required for cyclin F-mediated Cdh1 degradation.
Thus, we propose that SCFcyclin F-dependent degradation ex-
plains the requirement for D-box/Cy motif hybrid sequences in
Cdh1 that control its S-phase destabilization.
We propose that cyclin F is a key mediator of Cdh1 degrada-
tion and APC/C inactivation at G1/S. Importantly, cyclin F has the
ability to act prior to cyclin A, since it accumulates earlier during
the cell cycle (Figures 1A and S2; Bai et al., 1994). In addition,
since cyclin F catalyzes Cdh1 ubiquitylation, it provides a robust
and irreversible mechanism of APC/C inactivation. This is not un-
like the inactivation of CDK1 in mitosis, triggered by the APC/C-
dependent degradation of cyclin B. Since cyclin F and Cdh1 are
tightly intertwined biochemically, we predict that they possess
the necessary affinities for one another to mediate their rapid
ubiquitylation and degradation. These results raise the possibility
that the sole reason APC/C catalyzes cyclin F degradation is to
prevent its own inactivation in early G1 phase, thereby prevent-
ing premature S-phase entry. However, since cyclin F is non-
essential in HeLa and MEF cells, Cdh1 inactivation can be
compensated through other mechanisms. Functionally shifting
the responsibility of APC/C inactivation might be analogous to
the ability of cells to survive without canonical cyclins and
CDKs (Sherr and Roberts, 2004). Delineating the contributions
of these various components to APC/C inactivation and S-phase
entry in a single experimental system that directly measures the
start of DNA replication is an important area of future study.EXPERIMENTAL PROCEDURES
Mammalian Cell Culture and Immunoblotting
HEK293T and HeLa cells were obtained from ATCC and grown in DMEM
complete medium (Gibco) supplemented with 10% fetal bovine serum (FBS;
Atlanta Biologicals). T47D cells were also obtained from ATCC and grown in
RMPI-1640 medium with 10% FBS. RPE1-hTRET (FRT) cells, a kind gift
from Peter Jackson, were grown in DMEM complete medium (Gibco) supple-
mented with 10% FBS. The APC/C inhibitor proTame was purchased from
Boston Biochem.
All transfection experiments were performed in HEK293T. Transfections
were performed using Lipofectamine 2000 (Life Technologies). Cells
that had been transfected with protein expression vectors were cultured forCell Reports 16, 3359–3372, September 20, 2016 3369
24–48 hr prior to analysis. Samples for protein analysis by immunoblot were
lysed in NETN buffer (20 mM Tris-Cl [pH 8.0], 100 mM NaCl, 0.5 mM EDTA,
and 0.5% [v/v] Nonidet P-40 [NP-40]) supplemented with 2 mg/ml pepstatin,
2 mg/ml apoprotinin, 10 mg/ml leupeptin, 1 mM AEBSF (4-[2 Aminoethyl] ben-
zenesulfonyl fluoride), 1 mM Na3VO4, and 1 mM NaF. Lysis was performed on
ice for 20 min. Protein concentration was determined using Bradford (Bio-
Rad). Standard immunoblotting procedures were followed. Membranes
were blocked in 5% nonfat driedmilk (diluted in PBS 0.05% Tween 20 [PBST]).
RNAi and Crispr/Cas9 knockout reagents, including oligonucleotide se-
quences, are described in the Supplemental Experimental Procedures.
Immunoprecipitation
FLAG-tagged Cdh1 and Myc-tagged cyclin F (or mutants) were expressed in
HEK293T cells for 24 hr. All cells were treated with MG-132 (10 mM for 4 hr)
prior to lysis, dislodged by trypsinization, washed with PBS, lysed in NETN,
and clarified by centrifugation at 15,000 rpm for 15 min. Anti-FLAG M2,
or anti-Myc beads (20 ml per IP, Sigma, catalog no. F2426 and E6654, res-
pectively) were used to precipitate specific proteins (4h to overnight at 4C).
The beads were washed with NETN three times and eluted with Laemmli
sample buffer at 70C for 10 min. For endogenous cyclin F IP, 293T cells
were treated with 10 mMMG-132 for 6 hr. Lysates were precleared with Protein
A/G beads and mixed with cyclin F polyclonal rabbit antibody (sc-952) or
normal rabbit immunoglobulin G (IgG) (sc-2027) and 75 ml of equilibrated pro-
tein A/G beads.
In Vitro and In Vivo Ubiquitination Assay
Mutant or WT cyclin F proteins were translated in vitro in rabbit reticulocyte
lysate (Promega). G1 HeLa extract was prepared as described (Williamson
et al., 2009b). APC/C was captured on Protein A/G beads with an anti-
Cdc27 antibody (Santa Cruz Biotechnology), by rotating the bead slurry with
G1 extract on a rotary mixer for4 hr. In vitro ubiquitin assays were performed
by incubating 2.5 ml of in-vitro-translated substrate in 20- to 25-ml reactions
containing UBAB buffer (2.5 mM Tris-HCL [pH 7.5], 5 mM NaCl, and 1 mM
MgCl2), energy mix (15 mM creatine phosphate, 2 mM ATP, and 2 mM
MgCl2 [pH 8.0]), 4 mM DTT, 1.5 mg purified ubiquitin, 100 nM E1 (UBE1),
100 nM of E2 (UbcH5c or UBE2D3), and 5 ml of the APC/C-bead slurry. Ubiq-
uitin and E1 and E2 enzymes were purchased from Life Sensors. MG-132 was
added to prevent deubiquitylation. The reactions were terminated after 60 min
by boiling in sample buffer.
A FLAG-HIS ubiquitin construct (6-His-Flag-Ub) was a gift from Dr. Philippe
Soubeyran. For in vivo ubiquitylation assays, 80% of the cell suspension was
lysed in buffer 1 (6 M Guanidine-HCl, 0.1 M Na2HPO4/NaH2PO4, 0.01 M Tris/
HCl [pH 8.0], 15 mM imidazole, and 10 mM b-mercaptoethanol [bME]) and
used for pull-down of HIS-ubiquitin-conjugated proteins. The remaining 20%
was used to analyze inputs by immunoblot. The lysates used for pull-down
were sonicated to reduce viscosity and loaded onto 50 ml of Ni2+-NTA resin
pre-washed with buffer 1. Binding was performed at room temperature for
4 hr. The beads were successively washed with 750 ml of each of the following
buffers: buffer 1; buffer 2 (8M urea, 0.1 MNa2HPO4/NaH2PO4, 0.01M Tris/HCl
[pH 8.0], 10 mM bME); buffer 3 (8 M urea, 0.1 M Na2HPO4/NaH2PO4, 0.01 M
Tris/HCl [pH 6.3], 10mM bME) plus 0.2% Triton X-100; buffer 3 and then buffer
3 plus 0.1% Triton X-100. After the last wash, beads were eluted by incubating
in 50 ml of buffer 4 (200 mM imidazole, 0.15 M Tris/HCl [pH 6.7], 30% glycerol,
0.72 M bME, 5% SDS) for 20 min. Eluates were analyzed by immunoblot.
Cell-Cycle Analysis
HeLa S3 cells were synchronized in S-phase with double treatments with
2.5 mM thymidine. For flow cytometry analysis on RPE1, cells were treated
with siRNA targeting FF (control) of cyclin F for 24 hr. Serum was withdrawn
for 24 hr, and after refeeding entry in S-phase was monitored by propidium
iodide staining using standard protocols. U2OS cells were synchronized in
mitosis with nocodazole after siRNA. After release from nocodazole block,
cells were pulsed for 30 min with 10 mM EdU (Sigma # T511285) and then
trypsinized into a single-cell suspension, fixed in 3.7% formaldehyde, and
washed in PBS prior to EdU labeling by azide-alkyne cycloaddition click
chemistry. Alternatively, cells were fixed on plates in 3.7% formaldehyde. Click
reactions are a total of 500 ml in PBS and include Alexa Fluor 488 Azide (final3370 Cell Reports 16, 3359–3372, September 20, 2016concentration of 1 mM), CuSO4 (final concentration of 1 mM), and ascorbic
acid (final concentration of 100 mM, made fresh). The labeled cells were coun-
terstained for DNA with 7-AAD or Hoechst and either analyzed directly by flow
cytometry or imaging.
Statistical Analysis
Statistical significance was tested by t test or paired t test using the Prism sta-
tistical analysis software (GraphPad).
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